BNP Paribas Financial Markets
TRVI icon

BNP Paribas Financial Markets’s Trevi Therapeutics TRVI Stock Holding History

BNP Paribas Financial Markets’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$275K Buy
23,025
+969
+4% +$10.8K ﹤0.01% 3904
2025
Q4 		$276K Buy
22,056
+3,844
+21% +$44.4K ﹤0.01% 3906
2025
Q3 		$167K Sell
18,212
-12,784
-41% -$95.9K ﹤0.01% 4092
2025
Q2 		$170K Buy
30,996
+25,426
+456% +$158K ﹤0.01% 3836
2025
Q1 		$35K Sell
5,570
-2,116
-28% -$10.1K ﹤0.01% 4397
2024
Q4 		$31.7K Sell
7,686
-4,244
-36% -$13.6K ﹤0.01% 4588
2024
Q3 		$39.8K Buy
11,930
+6,764
+131% +$20.1K ﹤0.01% 3658
2024
Q2 		$15.4K Sell
5,166
-15,411
-75% -$42.8K ﹤0.01% 3674
2024
Q1 		$71K Sell
20,577
-111,632
-84% -$249K ﹤0.01% 3514
2023
Q4 		$177K Buy
132,209
+122,543
+1,268% +$186K ﹤0.01% 3258
2023
Q3 		$21.1K Sell
9,666
-1,183
-11% -$2.67K ﹤0.01% 3559
2023
Q2 		$25.9K Buy
+10,849
New +$27.3K ﹤0.01% 3568

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BNP Paribas Financial Markets's TRVI Position: Q1 2026 in Review

BNP Paribas Financial Markets increased its Trevi Therapeutics (TRVI) stake by 4.4% in Q1 2026, buying an estimated $10.8K and bringing the position to 23,025 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #3904.

BNP Paribas Financial Markets first reported a position in TRVI in Q2 2023 and has held it in 12 quarters since. The position peaked at $276K in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • BNP Paribas Financial Markets held 23,025 shares of Trevi Therapeutics worth $275K as of Q1 2026.
  • BNP Paribas Financial Markets bought 969 Trevi Therapeutics shares in Q1 2026, an estimated $10.8K.
  • Trevi Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q1 2026, its #3904 holding.
  • BNP Paribas Financial Markets first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • BNP Paribas Financial Markets's Trevi Therapeutics position peaked at $276K in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2026, filed 12 May 2026.